Home » Topics » Dermatologic, BioWorld Science

Dermatologic, BioWorld Science
RSS

Chymase inhibitors prevent intraperitoneal adhesion formation in hamsters

Jan. 28, 2004

RegeneRx licenses out European rights to TB4

Jan. 27, 2004

Azelaic acid found more effective than metronidazole in moderate papulopustular rosacea

Jan. 27, 2004

XMP-629 enters phase II for acne

Jan. 26, 2004

Enrollment completed in phase I Psoraxine trial

Jan. 26, 2004

Protective effects against UV irradiation reported for topical lycopene

Jan. 21, 2004

Galderma describes two series of RAR antagonists for dermatological disorders

Jan. 20, 2004

Initial dosing completed in phase I trial of MRE-0094

Jan. 16, 2004

Phase II trial confirms icatibant utility in hereditary angioedema

Jan. 15, 2004

End of patient enrollment announced for two clinical trials with Velac(R) Gel

Jan. 13, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent
BioWorld Science
Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...